FAST NEWS: Antengene Invests $36 Million in Drug Discovery Center

The latest: Biopharma company Antengene Corp. Ltd. (6996.HK) announced Monday it has entered into an agreement with a contractor to build a drug discovery and manufacturing center for antibody biologics in Hangzhou for 245.5 million yuan ($36.3 million). Looking up: Upon completion, the center will strengthen the company’s capabilities in drug development, manufacturing, and commercialization, to meet growing internal R&D needs and support its commercialization roadmap. Take Note: The project is expected to be completed in January 2025, meaning the company will still have to wait about two and a half…

Read More »

Online Medical Educator Huayiwang Seeks Growth Booster from IPO

The educational platform operator slipped into the red in the first five months of this year as it faces growing competition Key Takeaways: Hong Kong IPO candidate Huayiwang Technology recorded a loss in the first five months of the year, reversing steady profit growth over the previous three years The company’s paid subscriber growth has slowed and average spending per paid subscriber began to decline this year, raising concerns about its future By Molly Wen Doctors practice continuous learning in an effort to stay up with the latest treatment norms…

Read More »

Tim Hortons China Brews Up Explosive Growth Plan Using Tech and Localization

The soon-to-be U.S.-listed coffee chain is aiming for 2,750 Chinese stores by 2026, equal to nearly half of Starbuck’s current count Key Takeaways: Tim Hortons China is aiming to open nearly 3,000 stores in China over five years, banking on technology and localization to fuel its rapid expansion Company needs to be careful to avoid mistakes of chains like Costa and Krispy Kreme, which closed or sputtered after initially announcing similar major expansion plans By Doug Young Fasten your seat belts! Tim Hortons China, known locally as Tims China, is…

Read More »